The popularity of copyright’s blockbuster initially sparked a surge for pharma, but recent shifts present a complicated outlook for investors. Generic versions are reducing profits, and persistent patent challenges https://larapumw093789.uzblog.net/the-blue-pill-and-pharma-a-risky-investment-54819550